Rxivist logo

Sequential delivery of LAIV and SARS-CoV-2 in the ferret model can reduce SARS-CoV-2 shedding and does not result in enhanced lung pathology.

By Kathryn A Ryan, Katarzyna E Schewe, Jonathan Crowe, Susan A Fotheringham, Yper Hall, Richard Humphreys, Anthony C Marriott, Jemma Paterson, Emma Rayner, Francisco J. Salguero, Robert J Watson, Catherine J Whittaker, Miles W Carroll, Oliver Dibben

Posted 01 Feb 2021
bioRxiv DOI: 10.1101/2021.02.01.429110

Co-circulation of SARS-CoV-2 and influenza viruses could pose unpredictable risks to health systems globally, with recent studies suggesting more severe disease outcomes in co-infected patients. The lack of a readily available COVID-19 vaccine has reinforced the importance of influenza vaccine programmes during the COVID-19 pandemic. Live Attenuated Influenza Vaccine (LAIV) is an important tool in protecting against influenza, particularly in children. However, it is unknown whether LAIV administration might influence the outcomes of acute SARS-CoV-2 infection or disease. To investigate this, quadrivalent LAIV (QLAIV) was administered to ferrets 3 days pre- or post-SARS-CoV-2 infection. LAIV administration did not exacerbate SARS-CoV-2 disease course or lung pathology with either regimen. Additionally, LAIV administered prior to SARS-CoV-2 infection significantly reduced SARS-CoV-2 replication and shedding in the upper respiratory tract (URT). We conclude that LAIV administration in close proximity to SARS-CoV-2 infection does not exacerbate mild disease and can reduce SARS-CoV-2 shedding.

Download data

  • Downloaded 334 times
  • Download rankings, all-time:
    • Site-wide: 111,257
    • In microbiology: 7,796
  • Year to date:
    • Site-wide: None
  • Since beginning of last month:
    • Site-wide: 130,307

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide